Glucocorticoid receptor modulators to treat cervical cancer

Patent metadata

Field	Value
Publication number	US-10568880-B2
Application number	US-201816185271-A
Country	US
Kind code	B2
Filing date	Nov 9, 2018
Priority date	Mar 31, 2017
Publication date	Feb 25, 2020
Grant date	Feb 25, 2020

Abstract

Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.

First claim

What is claimed is:

1. A method of treating a subject hosting a cervical cancer tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and orally administering an effective amount of non-steroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load of the cervical cancer tumor, wherein the chemotherapeutic agent is selected from the group consisting of antimicrotubule agents, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors, antitumor antibiotics, intercalating agents, proteosome inhibitors, and combinations thereof, and wherein the SGRM is a fused azadecalin compound having the following formula:

wherein
L 1 and L 2 are members independently selected from a bond and unsubstituted alkylene;
R 1 is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, —OR 1A , NR 1C R 1D ,—C(O)NR 1C R 1D , and —C(O)OR 1A , wherein
R 1A is a member selected from hydrogen, unsubstituted alkyl and unsubstituted heteroalkyl,
R 1C and R 1D are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl,
wherein R 1C and R 1D are optionally joined to form an unsubstituted ring with the nitrogen to which they are attached, wherein said ring optionally comprises an additional ring nitrogen;
R 2 has the formula:

wherein
R 2G is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, —CN, and —CF 3 ;
J is phenyl;
t is an integer from 0 to 5;
X is —S(O 2 )—; and
R 5 is phenyl optionally substituted with 1-5 R 5A groups, wherein
R 5A is a member selected from hydrogen, halogen, —OR 5A1 , S(O 2 )NR 5A2 R 5A3 , —CN, and unsubstituted alkyl, wherein
R 5A1 is a member selected from hydrogen and unsubstituted alkyl, and
R 5A2 and R 5A3 are members independently selected from hydrogen and unsubstituted alkyl,
or salts and isomers thereof.

2. The method of claim 1 , wherein the chemotherapeutic agent is a taxane.

3. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of albumin-bound paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin, capecitabine, chlorambucil, cyclophosphamide, ifosfamide, melphalan, streptozocin, carmustine, lomustine, bendamustine, uramustine, estramustine, carmustine, nimustine, ranimustine, mannosulfan busulfan, dacarbazine, temozolomide, thiotepa, altretamine, 6-mercaptopurine (6-MP), cytarabine, floxuridine, fludarabine, hydroxyurea, methotrexate, pemetrexed, daunorubicin, doxorubicin, epirubicin, idarubicin, SN-38, ARC, NPC, campothecin, topotecan, 9-nitrocamptothecin, 9-aminocamptothecin, rubifen, gimatecan, diflomotecan, BN80927, DX-895 If, MAG-CPT, amsacrine, etoposide, etoposide phosphate, teniposide, doxorubicin, paclitaxel, docetaxel, accatin III, 10-deacetyltaxol, 7-xylosyl-10-deacetyltaxol, cephalomannine, 10-deacetyl-7-epitaxol, 7-epitaxol, 10-deacetylbaccatin III, 10-deacetyl cephalomannine, Irinotecan, Oxaliplatin, irinotecan liposome, and combinations thereof.

4. The method of claim 1 , wherein the fused azadecalin compound is (R)-(4a-ethoxymethyl-1-(4-fluorophenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1H,1,2,6-triaza-cyclopenta[b]naphthalene, which has the formula:

5. A method of treating a subject hosting a cervical cancer tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and orally administering an effective amount of non-steroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load of the cervical cancer tumor, wherein the chemotherapeutic agent is selected from the group consisting of antimicrotubule agents, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors, antitumor antibiotics, intercalating agents, proteosome inhibitors, and combinations thereof, and wherein the SGRM is an octahydro fused azadecalin compound having the following formula:

wherein
R 1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R 1a ;
each R 1a is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, N-oxide, and C 3-8 cycloalkyl;
ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;
each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkyl-C 1-6 alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , SR 2a , S(O)R 2a , S(O) 2R 2a , C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S;
alternatively, two R 2 groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R 2c groups;
R 2a , R 2b and R 2c are each independently selected from the group consisting of hydrogen and C 1-6 alkyl;
each R 3a is independently halogen; and
subscript n is an integer from 0 to 3,
or salts and isomers thereof.

6. The method of claim 5 , wherein the octahydro fused azadecalin compound is ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, which has the formula:

7. The method of claim 1 , wherein said oral administration of said SGRM comprises daily oral administration of said SGRM.

8. The method of claim 1 , wherein said oral administration of said SGRM comprises daily oral administration of said SGRM on one or more days selected from the group consisting of a day before administration of said chemotherapeutic agent, the day of administration of said chemotherapeutic agent, and a day after administration of said chemotherapeutic agent.

9. The method of claim 1 , wherein said oral administration of said SGRM comprises oral administration of said SGRM on the day of administration of said chemotherapeutic agent and also on one or both of a day before and a day after administration of said chemotherapeutic agent.

10. The method of claim 5 , wherein said oral administration of said SGRM comprises daily oral administration of said SGRM.

11. The method of claim 5 , wherein

Assignees

• Corcept Therapeutics Inc

Inventors

• Hunt Hazel

Classifications

• A61K31/4745 Primary

  condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title